11/21/2009. World Perspective on the Treatment of Mesothelioma: A few 2009 Highlights. Thierry M. Jahan, MD. But the incidence is rising
|
|
- Kimberly Clarke
- 8 years ago
- Views:
Transcription
1 Presenter Disclosures World Perspective on the Treatment of Mesothelioma: A few 2009 Highlights Personal financial relationships with commercial interests relevant to this presentation during the past 12 months: Research support: Eli Lilly, Genentech, Morphotek Consultant: Poniard Pharmaceuticals Thierry M. Jahan, MD Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology UCSF Diller Family Comprehensive Cancer Center Thoracic Oncology Program Personal financial relationships with non-commercial interests (e.g., government or other nonprofit funding) relevant to this presentation, within past 12 months: NONE Relevant institutional financial interests: NONE Personal financial relationships with tobacco industry entities within the past 3 years: NONE Mesothelioma, why does it matter? But the incidence is rising Overall, relatively small number of cases/yr 2000~ 3000/yr in US Concentrated more in areas of high asbestos exposure: Mining towns (Western Australia 6.6/10 5, in men over 35) Harbors/areas with large shipyard activity (Seattle, San Francisco/Oakland, New Orleans, Honolulu) /10 5 Certain hotspots (Libby MT, Sarnia Canada, Cappadocia Turkey) Untreated survival is measured in months Treatment can prolong survival and improve QOL Copyright restrictions may apply. Price, B. et al. Am. J. Epidemiol
2 SMRP as a Mesothelioma Screening Tool Soluble Mesothelin-Related Protein (SMRP): Marker of mesothelial cell differentiation split product of mesothelin SMRP levels are elevated in pleural and peritoneal fluid of pts with MPM In several retrospective analysis, SMRP had % specificity and 84-89% sensitivity in diagnosing MPM (Robinson Lancet 2003, Davies AJRCCM 2009 ) SMRP utility was studied prospectively in pts exposed to asbestos (Park AJRCCM 2008): N=538 subjects, 15 (3%) had elevated SMRP Elevated SMRP pts underwent w/u no MPM diagnosed WCLC 2009 update-holeevoet al 2 groups of patients from Belgian companies with history of asbestos use and from population seen at the Occupational Diseases Fund in Brussels G1: pts without asbestos related radiographic changes (N= 93, med age= 51) G2: pts with BENIGN asbestos related pulmonary disease (N= 102, med age= 64) 59 with pleural plaques 33 with diffuse pleural thickening Pts were followed for 2 yrs, with yearly blood sampling: SM levels a level > 2.5nM is considered elevated Renal function/gfr Mean baseline SM values: G1: 0.89 nm +/ G2: 1.24 nm +/ G2 pts with levels > 2.5 nm (1 pt with highest elevation of SM als with low GFR) No mesothelioma (or other Ca) diagnosed in this population during f/u Screening for Mesothelioma Mesothelioma is clearly a disease that could use a good screen Diagnosis is almost always made at an advanced stage Therapeutic options are limited and morbid Med survival is under 1 yr Latency bet exposure and diagnosis is measured in decades, and that is a huge problem for screening! Who do you screen? When do you start? When do you intervene? Ideal test for this disease should allow you to risk stratify as well as intervene in a timely fashion Conclusions on utility of SMRP Value of SMRP as screening tool likely to be limited With high sens/spec SMRP is an excellent tool for the DIAGNOSIS of MPM 2
3 Induction Chemotherapy for resectable MM NEW TREATMENT DEVELOPMENTS Usual rationale: Easier to administer chemo pre-op than post op Potentially eradicates microscopic disease? Potentially downstages making it an easier surgery? Patient selection: All non metastatic MPM (including N2) with biopsy confirmed mesothelioma and decent organ function No prior surgery (other than for diagnostics) Treatment: Cis-platin 75 mg/m 2 d1, Pemetrexed 500 mg/m 2 d1 q 21 days 4 cycles Planned surgery: EPP Planned post op RT: 54 Gy to operated hemithorax Krug JCO 2009 Induction Chemotherapy for resectable MM Results Pem/Cis-P followed by EPP, RT 77 pts enrolled, 73% men, med age 63 (34-78) 74% of pts completed planned chemo (12% PD, 2.5% died) 57% completed surgery(5% PD, 2.5% peri operative deaths) 52% completed planned RT (5% PD, 2.5% died) Total treatment related mortality= 9% Med OS= 16.8 mo ITT pop Med PFS= 10.1 mo ITT pop Krug JCO 2009 Krug JCO
4 Survival Results Explored Median overall survival for total population: 16.8 mo Median survival for pts WITHOUT radiographic response: 13.9 mo Median survival for pts WITH radiographic response: 26.1 mo Med OS for those who completed ALL Rx (52%): 29.1 mo Krug JCO 2009 Conclusions on Induction Therapy Appears promising Patient choice seems critical, but not too different from choice of candidates for EPP: Good PS Good Physiology ADVANCED DISEASE TREATMENT UPDATE Phase I trial of neo-adjuvant dasatinib in patients with resectable MPM DASATANIB: Oral agent ATP competitive inhibitor against Src kinase, BCR-ABL, c-kit, PDGFR, and ephrin receptor kinases Low toxicity profile : fluid retention, pleural/pericardial effusion, prolonged QTc, skin rash, TLS (CML) TREATMENT PLAN: Surgically resectable patients Initially staged through extensive surgical sequence Then 4 wks of dasatanib 70 mg po BID Followed by planned EPP or P/D Radiographic/mol responders receive additional 2 yrs of dasatanib after adjuvant RT/Chemo TSAO WCLC
5 MDACC Protocol Funding: DOD, BMS (drug) Dasatanib induction Results and Conclusions ESS: Mediastinoscopy Laparoscopy VATS or US Bx Day Weeks Oral Dasatinib Therapy EPP or Pleurectomy N=14 Radiographic response after 4 weeks: 2 MR, 8 SD, 2 too early to evaluate Molecular response: 2pts with MR had de-phosphorylation of p-srctyr 419 Assess eligibility PET-CT +/-MRI Labs Pre-op cardiac PFT Informed Consent Day -5 Blood/ Tissue Platelets/ Pleural Effusion collection in OR Day 7 Visit Blood collection Clinical Exam Day 14 Visit Blood collection Clinical Exam Day 21 Visit Blood collection Clinical Exam Day Blood/ Tissue Platelets/ Pleural Effusion Collection in OR PET-CT Of 4 pts with SD: 1 had min de-phosphorylation of p-srctyr no change in p-src Tyr increased phosphorylation p-srctyr 419 CONCLUSIONS: Subpopulation of MPM patients that may derive clinical benefit from dasatinib. Modulation of p-srctyr 419 is a reasonable pharmacodynamic marker for dasatinib treatment MPM is very heterogeneous. Molecular profiling will be necessary to ultimately optimize targeted therapy in this disease. Phase I trial of neo-adjuvant dasatinib in patients with resectable MPM This was a window of opportunity trial - Tissue is obtained as part of the patients preoperative evaluation for pre intervention evaluation - Tissue is obtained post op can assess effectiveness of agent on target: p-src-tyr 419 phosphorylation status Src inhibition was associated with some clinical activity: - Pts with MR had highest decrease in Src phosphorylation This study helps validate Src as a target in MPM: - CALGB finished enrolling is looking at dasatanib in unresectable, relapsed MPM with following correlative endpoints: Src phosphorylation on PBMC VEGF, PDGF, CSF-1 (Src depdt. activ. of MAPKK), MSRP Archival tissue for EphA2, PDGFR-β and their phosphorylation status Ph II Pazopanib In newly dx/relapsed MPM Pazopanib: oral VEGFR-1,2,3 PDGFR-α/β c-kit inhibitor Administered at 800 mg/d x 21 Decision rule: > 14/28 with 6mo PFS to continue N= 34, med age= 73, 82% men, 44% pre treated, majority of all pts had PS 1-2, med f/u= 8.1 mo 65% of pts had a Gr 3 AE, 12% Gr 4 AE Prev. Treated ORR Med OS Med PFS 47% 5.0 mo 2.0 mo Un treated 63% 14.4 mo 5.4 mo Only 10/28 met 6 mo PFS requirement so study stopped Molina et all WCLC
6 A pilot Ph II trial of the 20S proteosome inhibitor Bortezomib in patients with relapsed MPM Inhibitor of the 20S subunit of proteosome complex, good preclinical activity to justify clinical use in pts with relapsed MPM 1 prior therapy, PS 0-1, adequate heme/hepatic/renal fn B=1.6 mg/m2 weekly x 4 every 5 wks x 4 cycles or until progression 1 o obj= response, 2 o obj= OS, PFS, toxicity, Simon 2 stg design with need for 2 responses in first 23 pts to continue on to 2 nd stage 87% men, 96% PS 0-1, med age % pleural, 70% epi, 9% sarc, 4% biphasic, 17% NOS A pilot Ph II trial of the 20S proteosome inhibitor Bortezomib in patients with relapsed MPM N= 23 pt 1 pt with PR, 3 ineligible for resp, 19 pts with PD Median OS= 6.1 mo, median PFS= 2.1 mo Only 1 response seen, but needed 2 to continue to 2 nd stage Conclusion: BZ as single agent has minimal activity Fennell et al WCLC different single agent trials, similar results: - Acceptable toxicity profile. - Modest-likely cytostatic activityof the agent tested - No further development warranted as single agents These drugs join a growing list of targeted agents with similar results in MPM A phase I trial of cisplatin-pemetrexed-imatinib mesylate in patients with unresectable MPM Agent Gefitinib Erlotinib Vatalanib Sorafenib Imatinib Sunitinib Pazopanib Bortezomib Dasatanib Author Govindan/CALGB Garland/SWOG Jahan/CALGB Jänne/CALGB Porta/Ali/Mathy Nowak Molina/ Mayo Fennell Tsao/MDA Inhibitor of BCR-ABL protein, c-kit receptor, PDGF-R Commonly Used in : - CML - GIST tumors - Dermatofibrosarcoma protuberans Tsao et al WCLC
7 Phase I Cisplatin-Pemetrexed-Imatinib mesylate Unresectable Mesothelioma Chemo-naive KPS > 70 Dose Escalation of Imatinib Mesylate Cohort 1: 300 mg Cohort 2: 400 mg Cohort 3: 600 mg Cisplatin 75 mg/m 2 Pemetrexed 500 mg/m 2 IV every 3 weeks Imatinib mesylate orally daily Primary endpoint: Safety/Toxicity, DLT/MTD Secondary endpoints: OS, TTP, RR, QOL Preliminary Results DLT reached in cohort 3: - Nausea/vomiting - Cardiac event MTD: cisplatin 75 mg/m 2, pemetrexed 500 mg/m 2, imatinib 600 mg po daily Tissue analysis of PDGFR and serum PDGF pending Patient Summary Phase I cisplatin-pemetrexed-gleevec (n=17) Histology Best response Duration of Response (months) Dose of Agents Phase I cisplatin-pemetrexed-imatinib mesylate Preliminary Conclusions 1 Sarcomatoid SD 4 C 60 P 500 G Sarcomatoid INEV INEV C 60 P 500 G Biphasic PD 2 C 60 P 500 G Sarcomatoid PD 1 C 60 P 500 G Epitheliod SD/MR 4 C 75 P 500 G Epitheliod SD 12 C 75 P 500 G Epitheliod INEV 1 C 75 P 500 G Biphasic SD 16 C 75 P 500 G Sarcomatoid Mix SD/PR 3 C 75 P 500 G Epitheliod PR 8 C 75 P 500 G Biphasic SD 9++ C 75 P 500 G Sarcomatoid PD 2 C 75 P 500 G 600 Cisplatin-pemetrexed and imatinib mesylate is reasonably tolerated and may have activity in certain MPM patients. The MTD is cisplatin 75 mg/m 2 + pemetrexed 500 mg/m 2 + imatinib mesylate 600 mg po daily. DLT was nausea/vomiting and a cardiac event Targeting PDGFR in combination with platinum-pemetrexed should be studied further in MPM. 13 Sarcomatoid INEV DLT - nausea C 75 P 500 G * Epitheliod PR Still receiving Tx* C 75 P 500 G Epitheliod INEV DLT - MI C 75 P 500 G Epitheliod SD Still on trial C 75 P 500 G Epitheliod SD Still on trial C 75 P 500 G 600 7
8 How do we move forward We need better/more abundant target validation: - Dr. Tsao s paradigm: using a novel drug as induction therapy gives her access to plenty of post-op tissue to evaluate effect of drug on targets We need better biomarkers-predictive and prognostic - Correlative science components of these trials are extremely important We need more investigation into resistance mechanisms - Dr. Fennell and colleagues are looking in to Bortezomib resistance as part of the correlative analyses with their trial 2009 was a rich year with continued intense efforts in mesothelioma research worldwide These efforts continue to be quite necessary The US government has yet to ban asbestos We need more trials combining cytotoxics PLUS targeted drug: - Most targeted drugs are primarily cytostatic - Combinations can usually be carried out at full doses for cytotoxics with little or no PK interaction or overlap in toxicity - Dr. Tsao s pem/cis/imatinib showed decent activity, when there a had been none previously in the published efforts with imatinib 8
Malignant Mesothelioma State of the Art
Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG
More informationBrigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA
Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS 6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Patients with Resectable Malignant Pleural Mesothelioma
More informationMalignant Mesothelioma: an Update
Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationMesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
More informationSAKK Lung Cancer Group. Current activities and future projects
SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation
More informationManagement of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
More informationMesoPDT. Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI. Image Assisted Laser Therapy for Oncology
MesoPDT Photodynamic Therapy for malignant pleural mesothelioma ONCO-THAI Image Assisted Laser Therapy for Oncology Unité Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI "Image
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationPost-operative intrapleural chemotherapy for mesothelioma
Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationIdentifying New Targeted Therapies for Malignant Pleural Mesothelioma
Identifying New Targeted Therapies for Malignant Pleural Mesothelioma Anne S. Tsao, M.D. Assistant Professor June 27, 2008 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationPrincipal Investigator: Valerie W. Rusch, MD, FACS, Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Protocol 1101-1088 Phase I study of intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion: primary, metastases and mesothelioma Principal Investigator: Valerie W. Rusch, MD,
More informationOvarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
More informationASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology
ASCO Initiatives in Personalized Medicine Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology Financial Disclosures No financial relationships to disclose.
More informationTrials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
More informationNew Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationUpdate on Clinical Trials and Foundation Funded Grants
Update on Clinical Trials and Foundation Funded Grants Mary Hesdorffer, MS, APRN-BC Medical Liaison Meso Foundation www.curemeso.org Delivering the Diagnosis Delivering the Diagnosis Day 1 Taking control
More informationMechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
More informationLung Cancer and Mesothelioma
Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant
More informationSmall cell Lung cancer New Chemotherapy options. Nicolas Mach, MD,PD
Small cell Lung cancer New Chemotherapy options Nicolas Mach, MD,PD > 40 negative Phase III trials List of unsucessful drugs Pemetrexed, imatinib, bevacizumab, bcl-2 antagonist, ASCT, CASE PRESENTATION
More informationHow To Treat A Cancer With A Radical
Management of mesothelioma Jan.vanmeerbeeck@ugent.be Amsterdam, March 6, 2010 1 management Palliation Symptomatic care Pain Breathlessness Radiotherapy Chemotherapy Surgery Radical (intention to cure)
More informationPre-workshop exercise
Setting research priorities for mesothelioma workshop 10 th November 2014 Pre-workshop exercise Your individual ranking of unanswered questions about the diagnosis, treatment and care of mesothelioma Please
More informationMultiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma Untreated Initial Therapy Transplant eligible Multiple
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationMesothelioma. Information for Patients and Families. identifying and evaluating experimental
Mesothelioma CLINICAL TRIALS Information for Patients and Families identifying and evaluating experimental treatments table of contents Pg. 2... Phases of a Clinical Trial Pg. 3... Mesothelioma and Clinical
More informationNew Trends & Current Research in the Treatment of Lung Cancer, Pt. II
New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer
More informationExtrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos
More informationColumbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental
More informationMalignant Pleural Mesothelioma in Singapore
RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and
More informationClinical Indications and Results Following Chest Wall Resection
Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division
More informationPancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
More informationREPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
More informationHow To Treat Mesothelioma With A Tumor Stem Cell Inhibitor
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
More informationScreening, early referral and treatment for asbestos related cancer
Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationMesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam
Mesothelioma 2014 Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Disclosures Grants from Pfizer and Roche Advisor for MSD and Verastem Once upon a time. http://amlbenzene.net/diseases-asbestos.htm
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationMalignant pleural mesothelioma P/D vs. EPP
3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy
More informationWhat is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
More informationRound Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma
Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma I d like to welcome everyone, thanks for coming out to our lunch with experts. The faculty today are great people in the thoracic
More informationPharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationAdjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
More informationMalignant Pleural Diseases Advances Clinicians Should Know F Gleeson
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationMesothelioma Applied Research Foundation www.curemeso.org
Mesothelioma Applied Research Foundation www.curemeso.org Board of Directors Michael Becich PhD Gen. Steven Blum Lee Krug MD David Ettinger MD Axel Ranier Richard Mosca Erica Iacono Terry Lynch Hanne Minz
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationAccelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,
More information18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
More informationA succesfull case of HIPEC in a peritoneal mesothelioma patient
A succesfull case of HIPEC in a peritoneal mesothelioma patient Firmino, NLJ¹²; Miranda, E¹³; Oliveira, DA ²; Lima, MBA ¹²; Diniz, AF ¹²; Gomes, GES ¹²; Azevedo, LW ¹²; Soares,MC¹²; Gomes, ASA³. ¹Pernambuco
More informationMalignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious
More informationMesothelioma. 13th Perspectives in Lung Cancer March 10, 2012 Paul Baas, MD, PhD The Netherlands Cancer Institute
Treatment of Malignant Pleural Mesothelioma 13th Perspectives in Lung Cancer March 10, 2012 Paul Baas, MD, PhD The Netherlands Cancer Institute Advisor for Merck Sharp Dohme Advisor for Pfizer Teaching
More informationNavigating GIST. The Life Raft Group June 12, 2008
Navigating GIST Clinical Trials The Life Raft Group June 12, 2008 Some observations: Annually, only 3% of adult patients participate in cancer clinical trials. Lara et. al; Evaluation of factors affecting
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationH. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
More informationPRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology
PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI
More informationNational Clinical Trials Network Groups Update Fall 2014
National Clinical Trials Network Groups Update Fall 2014 Walter J Curran, Jr, MD An NRG Oncology Group Chair Executive Director Winship Cancer Institute of Emory University Atlanta, GA NCTN Groups Update
More informationMESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC
MESOTHELIOMA Not Just a Late Night Commercial Graciela Hoal, RN, MSN, ACNP-BC Saturday Session Thoracic Surgery Nurse Practitioner Greater Los Angeles Veteran Affairs Objectives Course Objectives: Discuss
More informationAdvances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope
Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationTreatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationTHE SECRETS OF OUR SUCCESS
THE SECRETS OF OUR SUCCESS QUALITY OF LIFE STUDIES OF THE NCIC Andrea Bezjak, MDCM, MSc,, FRCPC Chair, NCIC CTG QOL Committee Outline of the Presentation Can we consider NCIC CTG QOL activities a success?
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationTHE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA
THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA Mitchell Keegan, Ph.D. Vice President of Development, Verastem, Inc. 1
More informationUMHS-PUHSC JOINT INSTITUTE
Imaging Biomarkers for Staging and Assessing Response to Therapy in Multiple Myeloma Qian Dong, MD. Radiology University of Michigan Wei Guo, MD. Orthopedic Oncology Peking University Second Hospital Team
More informationPARP Inhibitors in Lung Cancer. Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center
PARP Inhibitors in Lung Cancer Primo N. Lara, Jr., MD Professor of Medicine UC Davis Comprehensive Cancer Center Poly (ADP-ribose) Polymerase (PARP): Mechanism of Action PARPs: family of enzymes that repair
More informationPrinciples of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationShould we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
More informationCancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
More informationSurvey of Mesothelioma Associated with Asbestos Exposure in Japan
The research and development and the dissemination projects related to the 13 fields of occupational injuries and illnesses Survey of Mesothelioma Associated with Asbestos Exposure in Japan Clinical characteristics
More informationFrequency of NHL Subtypes in Adults
Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults
More informationPROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.
PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic
More informationEndpoint Selection in Phase II Oncology trials
Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles
More informationLondon Cancer. Mesothelioma Lung Protocols
London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationClinical Trials for Patients with
Clinical Trials for Patients with Malignant Pleural Mesothelioma Lee M. Krug, M.D. Memorial Sloan-Kettering Cancer Center New York, New York Challenges in MPM Clinical Trials Mesothelioma is a rare disease,
More informationMalignant Mesothelioma
Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
More informationMalignant Mesothelioma
Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
More informationEvaluation of asbestos-exposure, clinical diagnosis and treatment of MPM
Evaluation of asbestos-exposure, clinical diagnosis and treatment of MPM Aija Knuuttila, MD, PhD Dept. of Pulmonary Medicine Helsinki University Central Hospital, Finland 15.11.2007 Malignant pleural mesothelioma
More informationMALIGNANT PLEURAL MESOTHELIOMA
MALIGNANT PLEURAL MESOTHELIOMA Giovanni Luca Ceresoli Thoracic & GU Oncology Unit Humanitas Gavazzeni, Bergamo Unmet needs in MPM WCLC 2013 1. Role of surgery and radiotherapy (IMRT) 2. How to improve
More informationSummary ID# 13095. Clinical Study Summary: Study H3E-EW-B012
Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically
More informationRole of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases
Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly
More informationMoving forward, where are we with Clinical Trials?
Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where
More information1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
More informationLessons learned from the Western Australian experience with mesothelioma
Lessons learned from the Western Australian experience with mesothelioma Alison Reid, Western Australian Institute for Medical Research In partnership with Nick de Klerk, Nola Olsen, Jan Sleith, Geoffrey
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationUnderstanding Pleural Mesothelioma
Understanding Pleural Mesothelioma UHN Information for patients and families Read this booklet to learn about: What is pleural mesothelioma? What causes it? What are the symptoms? What tests are done to
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More information